Tevogen Bio Holdings Inc. (TVGN) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Tevogen Bio Holdings Inc. (TVGN) has a cash flow conversion efficiency ratio of 0.278x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.73 Million) by net assets ($-9.84 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See TVGN defensive asset coverage days to measure how many days the company can operate on defensive assets alone.
Tevogen Bio Holdings Inc. - Cash Flow Conversion Efficiency Trend (2022–2025)
This chart illustrates how Tevogen Bio Holdings Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data.
Tevogen Bio Holdings Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Tevogen Bio Holdings Inc. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Wisher Industrial Co Ltd
TW:1465
|
-0.178x |
|
The Berkeley Group Holdings plc
LSE:BKG
|
0.041x |
|
Sunny Elec
KO:004770
|
0.021x |
|
Canterra Minerals Corporation
V:CTM
|
-0.091x |
|
Spuntech
TA:SPNTC
|
0.036x |
|
InkTec Co. Ltd
KQ:049550
|
0.033x |
|
Wir Asia Tbk PT
JK:WIRG
|
0.022x |
|
Vanfund Urban Investment & Development Co Ltd
SHE:000638
|
0.085x |
Annual Cash Flow Conversion Efficiency for Tevogen Bio Holdings Inc. (2022–2025)
The table below shows the annual cash flow conversion efficiency of Tevogen Bio Holdings Inc. from 2022 to 2025. For the full company profile with market capitalisation and key ratios, see Tevogen Bio Holdings Inc. market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-06-30 | $-6.67 Million | $-12.00 Million | 1.798x | +1977.65% |
| 2024-06-30 | $-94.43 Million | $-8.17 Million | 0.087x | -66.06% |
| 2023-06-30 | $-33.95 Million | $-8.66 Million | 0.255x | -20.31% |
| 2022-06-30 | $-16.49 Million | $-5.27 Million | 0.320x | -- |
About Tevogen Bio Holdings Inc.
Tevogen Bio Holdings Inc., a clinical-stage specialty immunotherapy company, develops off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and other disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment of ambulatory high-risk adult COVID-19 patients; and in Phase 1 clinical trial to treat acute SARS-CoV-2 pa… Read more